ABL1 (Abelson murine leukemia viral oncogene homolog 1), also known as c-Abl, is a non-receptor tyrosine kinase encoded by the ABL1 gene on chromosome 9q34. This 120 kDa protein is a member of the Abelson family of tyrosine kinases and plays critical roles in numerous cellular processes including actin cytoskeleton organization, cell adhesion, DNA damage response, and synaptic function 1. In the nervous system, ABL1 is involved in neuronal development, axonal guidance, and synaptic plasticity. Notably, ABL1 activation has been implicated in the pathogenesis of several neurodegenerative diseases, including Alzheimer's Disease and Parkinson's Disease, making it an interesting therapeutic target 2.
| ABL1 Protein | |
|---|---|
| Protein Name | ABL1 Tyrosine Kinase (c-Abl) |
| Gene | [ABL1](/genes/abl1) |
| UniProt ID | [P00519](https://www.uniprot.org/uniprot/P00519) |
| PDB ID | 1AB2, 2FO0, 4MVG, 6AMN, 5A1E |
| Molecular Weight | ~120 kDa |
| Subcellular Localization | Cytoplasm, nucleus |
| Protein Family | Tyrosine Kinase (non-receptor) |
| Tissue Expression | Ubiquitous, high in brain |
ABL1 is a modular protein containing multiple functional domains:
The N-terminal SH3 (Src Homology 3) domain is involved in protein-protein interactions through proline-rich sequences. In the inactive conformation, the SH3 domain maintains ABL1 in a low-activity state by binding to its own linker region 3.
The SH2 (Src Homology 2) domain recognizes phosphorylated tyrosine residues, allowing ABL1 to bind to other tyrosine-phosphorylated proteins. This domain is also involved in autoinhibition when bound to the kinase domain 4.
The catalytic kinase domain possesses the classic bilobal structure typical of protein kinases. It contains the activation loop (A-loop) whose phosphorylation state determines kinase activity. ABL1 can autophosphorylate itself (autophosphorylation) or be activated by other kinases 5.
The ABL1 gene produces two major splice variants:
ABL1 is a key regulator of actin cytoskeleton dynamics. It promotes actin polymerization and stress fiber formation through interactions with various cytoskeletal proteins. ABL1 localizes to actin-rich structures including lamellipodia, filopodia, and focal adhesions, where it coordinates actin remodeling necessary for cell motility and morphology 6.
Through its effects on the cytoskeleton, ABL1 influences cell adhesion and migration. ABL1 localizes to focal adhesions and regulates the dynamics of integrin-mediated adhesion complexes. This function is particularly important in neuronal migration during brain development 7.
In the nucleus, ABL1 participates in the DNA damage response. Following genotoxic stress, ABL1 is activated and translocates to sites of DNA damage where it phosphorylates various substrates involved in cell cycle arrest, DNA repair, and apoptosis. ABL1 interacts with p53 and other DNA damage response proteins 8.
In neurons, ABL1 is localized at synapses where it regulates:
ABL1 regulates progression through the cell cycle, particularly at the G1/S transition and mitosis. Dysregulation of ABL1 can lead to uncontrolled proliferation, which is why ABL1 was first characterized as an oncogene 10.
ABL1 is activated in response to amyloid-beta (Aβ) pathology and contributes to several aspects of AD pathogenesis:
Exposure of neurons to amyloid-beta leads to ABL1 activation through oxidative stress and calcium-mediated pathways. Activated ABL1 then:
Studies show that ABL1 activation precedes neuronal death in AD models, suggesting ABL1 may be a mediator of Aβ toxicity 11.
ABL1 phosphorylates tau protein at multiple tyrosine residues. While tau is primarily phosphorylated at serine/threonine sites in AD, tyrosine phosphorylation by ABL1 may:
ABL1 activation contributes to synaptic deficits in AD through:
ABL1 inhibitors, particularly imatinib, have shown neuroprotective effects in AD models:
However, BBB penetration remains a challenge 12.
ABL1 has emerged as a significant player in PD pathogenesis:
Alpha-synuclein aggregation activates ABL1. Studies show:
ABL1 affects mitochondrial function in PD:
Abl1 activation in microglia promotes neuroinflammation:
Imatinib and other ABL1 inhibitors show promise in PD models:
Clinical trials of imatinib in PD are ongoing 14.
In HD, mutant huntingtin protein activates ABL1:
Abl1 is involved in:
Abl1 is activated following cerebral ischemia:
| Drug | Status | Notes |
|---|---|---|
| Imatinib (Gleevec) | Approved (CML) | Being repurposed for neurodegeneration |
| Nilotinib | Approved (CML) | Better BBB penetration |
| Bosutinib | Approved (CML) | Under investigation |
| Radotinib | Approved (CML) | Limited brain penetration |
| Partner Protein | Interaction Type | Functional Consequence |
|---|---|---|
| p53 | phosphorylation | DNA damage response |
| Rb | phosphorylation | Cell cycle control |
| Crk | SH3 binding | Cytoskeletal regulation |
| Rad51 | phosphorylation | DNA repair |
| NMDA Receptor | phosphorylation | Synaptic function |
Several clinical trials are investigating ABL1 inhibitors in neurodegenerative diseases:
Results have been mixed, highlighting the need for better biomarkers and patient selection 17.